Saving sight in China and beyond: The lifeline express model

BMJ Global Health

Volumn 3, Issue 4, 2018, Pages

  Wong, Ian Yat Hin ^a   Ni, Michael Yuxuan ^a   Wong, Irene Oi Ling ^a   Fong, Nellie ^b,c   Leung, Gabriel M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Lifeline Express Hong Kong Foundation   (China)

^c Chinese Foundation for Lifeline Express   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85061814773     PISSN: None     EISSN: 20597908     Source Type: Journal    
DOI: 10.1136/bmjgh-2018-000766     Document Type: Article

References (34)

1. Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA 2017;317:2515-23.
2. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007;14:179-83.
3. Frank RN. Diabetic retinopathy. N Engl J Med 2004;350:48-58.
4. Cheung N, Wong IY, Wong TY. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care 2014;37:900-5.
5. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193-203.
6. Prescott G, Sharp P, Goatman K, et al. Improving the cost-effectiveness of photographic screening for diabetic macular oedema: a prospective, multi-centre, UK study. Br J Ophthalmol 2014;98:1042-9.
7. Rachapelle S, Legood R, Alavi Y, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology 2013;120:566-73.
8. Kawasaki R, Akune Y, Hiratsuka Y, et al. Cost-utility analysis of screening for diabetic retinopathy in Japan: a probabilistic Markov modeling study. Ophthalmic Epidemiol 2015;22:4-12.
9. Lian JX, Gangwani RA, McGhee SM, et al. Systematic screening for diabetic retinopathy (DR) in Hong Kong: prevalence of DR and visual impairment among diabetic population. Br J Ophthalmol 2016;100:151-5.
10. Thomas RL, Dunstan F, Luzio SD, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 2012;344:e874.
11. Standards of medical care in diabetes-2015: summary of revisions. Diabetes care 2015;38(Suppl S4).
12. Blumenthal D, Hsiao W. Privatization and its discontents - the evolving Chinese health care system. N Engl J Med 2005;353:1165-70.
13. Yip WC, Hsiao WC, Chen W, et al. Early appraisal of China's huge and complex health-care reforms. Lancet 2012;379:833-42.
14. Cheng TM. Early results of China's historic health reforms: the view from minister Chen Zhu. Interview by Tsung-Mei Cheng. Health Aff 2012;31:2536-44.
15. Blumenthal D, Hsiao W. Lessons from the East-China's rapidly evolving health care system. N Engl J Med 2015;372:1281-5.
16. Ophthalmology ICo. Number of ophthalmologists in practice and training worldwide. 2018. http://www.icoph.org/ophthalmologistsworldwide.html
17. Harding S, Greenwood R, Aldington S, et al. Grading and disease management in national screening for diabetic retinopathy in England and Wales. Diabet Med 2003;20:965-71.
18. Mathers CD, Fat DM, Inoue M, et al. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ 2005;83:171-7.
19. Fleming S, Atherton H, McCartney D, et al. Self-screening and non-physician screening for hypertension in communities: a systematic review. Am J Hypertens 2015;28:1316-24.
20. Keenum Z, McGwin G, Witherspoon CD, et al. Patients' adherence to recommended follow-up eye care after diabetic retinopathy screening in a publicly funded county clinic and factors associated with follow-up eye care use. JAMA Ophthalmol 2016;134:1221-8.
21. Mtuya C, Cleland CR, Philippin H, et al. Reasons for poor follow-up of diabetic retinopathy patients after screening in Tanzania: a cross-sectional study. BMC Ophthalmol 2016;16:115.
22. National Development and Reform Commission MoFA, and Ministry of Commerce of the People's Republic of China. Vision and actions on jointly building Silk Road Economic Belt and 21st century Maritime Silk Road. 2015. Chapters I-V (accessed 25 Jan 2018).
23. Hu R, Liu R, Hu N. China's Belt and Road Initiative from a global health perspective. Lancet Glob Health 2017;5:e752-e753.
24. Horton R. Offline: Are China's global ambitions good for global health? Lancet 2018;390:2752.
25. Commission NHaFP. NHFPC's implementation plan for the Belt and Road medical and health cooperation (2015-2017), 2015.
26. Tang K, Li Z, Li W, et al. China's Silk Road and global health. Lancet 2017;390:2595-601.
27. Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 2008;115:1869-75.
28. Scanlon PH, Stratton IM, Leese GP, et al. Screening attendance, age group and diabetic retinopathy level at first screen. Diabet Med 2016;33:904-11.
29. Scotland G, McKeigue P, Philip S, et al. Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland. Diabet Med 2016;33:886-95.
30. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948-59.
31. Andermann A, Blancquaert I, Beauchamp S, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317-9.
32. Center CINI. The 40th China Statistical Report on Internet Development. 2017. http://www.cnnic.net.cn/hlwfzyj/hlwxzbg/hlwtjbg/201708/P020170807351923262153.pdf
33. Outline of the healthy China 2030 Plan. 2016 http://www.gov.cn/zhengce/2016-10/25/content_5124174.htm (accessed 10 Jan 2017).
34. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007;298:902-16.